Regen BioPharma (Regen BioPharma) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma ROE % Adjusted to Book Value?

Regen BioPharma's ROE % for the quarter that ended in Mar. 2024 was 0.00%. Regen BioPharma's PB Ratio for the quarter that ended in Mar. 2024 was N/A. Regen BioPharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was N/A.

Regen BioPharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Regen BioPharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma ROE % Adjusted to Book Value Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

Negative Equity

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regen BioPharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Regen BioPharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's ROE % Adjusted to Book Value falls into.

Regen BioPharma ROE % Adjusted to Book Value Calculation

Regen BioPharma's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

Regen BioPharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Regen BioPharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.